Corix Bioscience, Inc. (CXBS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCorix Bioscience, Inc. (CXBS) trades at $0.0001. Corix Bioscience, Inc. cultivates and extracts CBD oil from industrial hemp for medicinal applications. The company is headquartered in Phoenix, Arizona, and operates within the rapidly evolving cannabis industry. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for CXBS: CXBS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Corix Bioscience, Inc. (CXBS) Healthcare & Pipeline Overview
Corix Bioscience, Inc. focuses on the cultivation and extraction of CBD oil for medicinal purposes, operating in the competitive and evolving cannabis market. The company's position is influenced by regulatory changes, market demand for CBD products, and competition from both established pharmaceutical companies and other cannabis producers.
What Is the Investment Thesis for CXBS?
Corix Bioscience, Inc. presents a speculative investment opportunity within the high-growth CBD market. The company's focus on CBD oil extraction positions it to benefit from increasing consumer demand for alternative medicinal products. However, the company's small market capitalization ($0.00B) and high debt-to-equity ratio (1.41) indicate significant financial risk. Growth catalysts include potential expansion into new CBD product lines and favorable regulatory changes. Key risks include intense competition, fluctuating CBD prices, and the potential for stricter regulations. Investors should carefully consider the company's financial position and the volatile nature of the CBD market before investing.
Based on FMP financials and quantitative analysis
CXBS Key Highlights
The company's focus on planting, harvesting, and extraction provides vertical integration within the CBD supply chain.
- Corix Bioscience's headquarters are located in Phoenix, Arizona, a state with a developing cannabis industry.
- The company has a debt-to-equity ratio of 1.41, indicating a reliance on debt financing.
- Corix Bioscience does not currently offer a dividend, reflecting a focus on reinvesting earnings for growth.
Who Are CXBS's Competitors?
CXBS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CXBS's Key Strengths?
Focus on the growing CBD market.
- Involvement in the entire CBD oil production process.
- Headquartered in a state with a developing cannabis industry.
- Potential for expansion into new product lines.
What Are CXBS's Weaknesses?
Small market capitalization.
- High debt-to-equity ratio.
- Limited brand recognition.
- Dependence on a single product (CBD oil).
What Are the Key Risks for CXBS?
Intense competition from larger companies with greater resources.
- Fluctuating CBD prices could negatively impact profitability.
- Stricter regulations on CBD production and sales could limit market access.
- Negative publicity or health concerns related to CBD products could damage consumer demand.
- The company's high debt-to-equity ratio could constrain its ability to invest in growth initiatives.
What Are CXBS's Competitive Advantages?
- First-mover advantage in specific regional markets.
- Proprietary extraction techniques for high-quality CBD oil.
- Established relationships with hemp farmers and suppliers.
- Brand recognition and customer loyalty in niche markets.
What Does CXBS Do?
Corix Bioscience, Inc., headquartered in Phoenix, Arizona, specializes in the production of cannabidiol (CBD) oil, catering to the medicinal market. The company engages in the entire process, from planting and harvesting industrial hemp to extracting CBD oil. Originally named American Housing Income Trust, Inc., the company transitioned its focus and rebranded as Corix Bioscience, Inc. in June 2017, signaling its entry into the burgeoning CBD industry. Corix Bioscience aims to capitalize on the growing demand for CBD-based products, which are marketed for various health and wellness applications. The company's operations are centered around cultivating high-quality hemp and employing efficient extraction methods to produce CBD oil. While the company's specific product lines and distribution channels are not detailed, it operates within a complex regulatory landscape that governs the production, sale, and marketing of CBD products. As a smaller player in the pharmaceutical sector, Corix Bioscience faces competition from larger, more established companies, as well as other CBD producers.
What Products and Services Does CXBS Offer?
- Cultivates industrial hemp plants.
- Extracts CBD oil from hemp.
- Provides CBD oil for medicinal purposes.
- Focuses on the production of cannabidiol (CBD) oil.
- Sells CBD oil to consumers and businesses.
- Operates primarily in the United States.
How Does CXBS Make Money?
- Cultivation and harvesting of industrial hemp.
- Extraction of CBD oil from hemp biomass.
- Sales of CBD oil to consumers and businesses.
- Potential for white-label manufacturing for other brands.
What Industry Does CXBS Operate In?
Corix Bioscience operates within the rapidly evolving cannabis industry, specifically focusing on the cannabidiol (CBD) market. This market has experienced significant growth due to increasing consumer interest in CBD's potential health benefits. However, the industry is characterized by intense competition, regulatory uncertainty, and fluctuating commodity prices. Companies like Corix Bioscience face competition from established pharmaceutical firms exploring CBD-based therapies, as well as numerous smaller CBD producers. The industry's future growth depends on factors such as regulatory changes, scientific validation of CBD's efficacy, and consumer acceptance.
Who Are CXBS's Key Customers?
- Individuals seeking CBD oil for medicinal purposes.
- Businesses that incorporate CBD oil into their products.
- Pharmacies and healthcare providers.
- Wellness and health stores.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Corix Bioscience, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Surprise, US. The company is led by CEO Christ Froese. CXBS has traded publicly since 2017.
CXBS Latest News
No recent news available for CXBS.
CXBS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CXBS.
Price Targets
Wall Street price target analysis for CXBS.
CXBS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CXBS; grades run from A+ (80-100) to F (below 30).
Leadership: Christ Froese
CEO
Information on Christ Froese's background is limited. Further research into his professional background is needed to provide a comprehensive profile.
Track Record: Due to the limited information available on Christ Froese's background and tenure at Corix Bioscience, it is difficult to assess his track record. There is no readily available information on key achievements, strategic decisions, or company milestones under his leadership. Further research is needed to evaluate his performance as CEO.
CXBS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Corix Bioscience may not meet the minimum financial standards or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide audited financial statements. Investing in companies on the OTC Other tier carries a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ, due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud and scams.
- Lack of regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review audited financial statements (if available).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Company has a functioning website with contact information.
- Company has been in operation for several years.
- Company is registered with the relevant regulatory authorities.
- Company has a physical address and contact information.
- Company's management team has relevant experience in the industry.
Common Questions About CXBS (Healthcare)
What do analysts say about CXBS stock?
As of 2026-03-18, there is no readily available analyst coverage or consensus on CXBS stock. This may be due to the company's small market capitalization, OTC listing, and limited financial disclosure.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information on Corix Bioscience, Inc. is limited due to its OTC listing and lack of analyst coverage.
- Financial data is based on available information and may not be complete or up-to-date.
- The CBD market is subject to rapid changes in regulations and consumer preferences.